BioSpace News Archive

Array BioPharma today reported results for its first quarter of fiscal 2018 and provided an update on the progress of its key clinical development programs.

Xencor announced that it will release third quarter 2017 financial results after the market closes on Tuesday, November 7, 2017.

The collaboration will bring together Arcturus’s LUNAR lipid-mediated delivery platform with Synthetic Genomics’ RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics.

Citius’ investigational program for Mino-Lok is designated “Fast Track” and is currently starting up sites for a phase III trial of Mino-Lok in the U.S.

The Phase I trial will investigate the comparative bioavailability of INP104 versus two approved DHE formulations.

RegeneRx today announced the results of its phase III dry eye trial sponsored by its U.S. joint venture, ReGenTree, LLC.

Soligenix announced that it has entered into definitive agreements with investors for the purchase and sale of 1,575,500 shares of common stock at a price of $2.00 per share in a registered direct offering and 982,000 shares of common stock at a purchase price of $2.00 per share in a concurrent private placement.

Medizone today announced the appointment of Philip A. Theodore, as its Executive VP-Operations and Administration, General Counsel and Corporate Secretary.

The oral tablet formulation of CR845 was developed in accordance with a Manufacturing and Clinical Supply Agreement between Cara Therapeutics and Enteris whereby Enteris utilized its Peptelligence technology to enable the active ingredient.

For the three months ended September 30, 2017, compared to the corresponding period of 2016, Semler had revenue of $3,607,000, an increase of $1,625,000, compared to $1,982,000